Thoracic cancer · 2026
Efficacy and Safety of Immune Checkpoint Inhibitors for Lung Cancer Complicated by Interstitial Pneumonia: The CS-Lung 003 Study, Branch Number 28.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hamai Kosuke, Kanaji Nobuhiro, Watanabe Naoki, Ishikawa Nobuhisa, Ueno Sayaka, Masuda Takeshi, Hattori Noboru, Yamasaki Masahiro, Matsumoto Naoko, Nakanishi Masamoto, Fujimoto Nobukazu, Takigawa Nagio, Nishii Kazuya, Hotta Katsuyuki, Kiura Katsuyuki
Аннотация
BACKGROUND: Immune checkpoint inhibitors (ICIs) improve the prognosis of patients with previously treated non-small cell lung cancer (NSCLC). However, the efficacy and safety of ICIs for patients with NSCLC complicated with interstitial pneumonia (IP) remain unknown. This study aimed to analyze patients with NSCLC and IP treated with ICIs and to investigate the efficacy and exacerbation frequency of ICI therapy.
METHODS: We prospectively enrolled patients with NSCLC and IP at multiple centers and examined progression-free survival (PFS) and overall survival (OS) using the Kaplan-Meier method.
RESULTS: The median PFS was 5.8 months, and the median OS was 9.7 months. ICI-related lung injury was observed in seven of the 19 patients (36.8%). Pneumonitis was observed in one of five patients with a usual interstitial pneumonia (UIP) pattern and in six of 14 patients with a non-UIP pattern; however, there was no significant difference in onset frequency. Furthermore, we observed no significant difference in PFS between patients with and without ICI-related pneumonitis (6.8 vs. 3.3 months, respectively; p = 0.826). OS tended to be shorter in patients with ICI-related pneumonitis, but the difference was not significant (8.0 vs. 16.7 months, respectively; p = 0.172).
CONCLUSIONS: The use of ICIs in patients with NSCLC and IP produces long-term responses in some cases; however, there is a high possibility of ICI-related pneumonitis. In cases where the condition worsens, post-treatment may be difficult, and the prognosis may be poor.
METHODS: We prospectively enrolled patients with NSCLC and IP at multiple centers and examined progression-free survival (PFS) and overall survival (OS) using the Kaplan-Meier method.
RESULTS: The median PFS was 5.8 months, and the median OS was 9.7 months. ICI-related lung injury was observed in seven of the 19 patients (36.8%). Pneumonitis was observed in one of five patients with a usual interstitial pneumonia (UIP) pattern and in six of 14 patients with a non-UIP pattern; however, there was no significant difference in onset frequency. Furthermore, we observed no significant difference in PFS between patients with and without ICI-related pneumonitis (6.8 vs. 3.3 months, respectively; p = 0.826). OS tended to be shorter in patients with ICI-related pneumonitis, but the difference was not significant (8.0 vs. 16.7 months, respectively; p = 0.172).
CONCLUSIONS: The use of ICIs in patients with NSCLC and IP produces long-term responses in some cases; however, there is a high possibility of ICI-related pneumonitis. In cases where the condition worsens, post-treatment may be difficult, and the prognosis may be poor.